Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers


Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers

RESEARCH TRIANGLE PARK, N.C. (April 17, 2012) — Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology announces that Metabolon and Takeda Pharmaceutical Company Limited (TSE: 4502), a global pharmaceutical company, have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.

Metabolon has developed a proprietary analytical platform and software for biomarker discovery using metabolomics to accelerate drug discovery and development by accurately measuring the spectrum of biochemical changes in biological samples, and mapping these changes to their corresponding metabolic pathways. Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.

Metabolon’s CEO John Ryals said, “We are excited about the prospect of collaborating with Takeda to accelerate its research programs. Metabolon has built a unique platform and has accumulated a vast amount of institutional knowledge in the field of metabolome analysis. We believe that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and more informed decisions.

About Takeda Pharmaceutical Company Limited:
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website

About Metabolon
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 350 client studies and processed over 50,000 samples for customers in 2011 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit or contact Philippe Chemla at or 919-572-1711.

Media Contact:
Mackenzie Mills